Supramolecular host-guest nanosystems for overcoming cancer drug resistance [0.03%]
用于克服癌症药物抵抗的超分子主客体纳米系统
Sha Wu,Miaomiao Yan,Minghao Liang et al.
Sha Wu et al.
Cancer drug resistance has become one of the main challenges for the failure of chemotherapy, greatly limiting the selection and use of anticancer drugs and dashing the hopes of cancer patients. The emergence of supramolecular host-guest na...
Emerging roles of 3D-culture systems in tackling tumor drug resistance [0.03%]
三维培养系统在克服肿瘤药物耐受方面发挥的新作用
Amin Nikdouz,Francesca Orso
Amin Nikdouz
Drug resistance that affects patients universally is a major challenge in cancer therapy. The development of drug resistance in cancer cells is a multifactor event, and its process involves numerous mechanisms that allow these cells to evad...
Victoria A Remley,Joel Linden,Todd W Bauer et al.
Victoria A Remley et al.
Tumors survive by creating a tumor microenvironment (TME) that suppresses antitumor immunity. The TME suppresses the immune system by limiting antigen presentation, inhibiting lymphocyte and natural killer (NK) cell activation, and facilita...
Targeting BCL2 pathways in CLL: a story of resistance and ingenuity [0.03%]
在CLL中靶向BCL2通路：一个关于抵抗和创新的故事
Amanda Reyes,Tanya Siddiqi
Amanda Reyes
Chronic lymphocytic leukemia (CLL) is common amongst leukemic malignancies, prompting dedicated investigation throughout the years. Over the last decade, the treatment for CLL has significantly advanced with agents targeting B-cell lymphoma...
Gül Kozalak,Ali Koşar
Gül Kozalak
Multiple myeloma (MM) is a type of hematological cancer that occurs when B cells become malignant. Various drugs such as proteasome inhibitors, immunomodulators, and compounds that cause DNA damage can be used in the treatment of MM. Autoph...
Sachin Sharma,Oksana Chepurna,Tao Sun
Sachin Sharma
As the most common and aggressive type of primary brain tumor in adults, glioblastoma is estimated to end over 10,000 lives each year in the United States alone. Stand treatment for glioblastoma, including surgery followed by radiotherapy a...
Recent advances in natural compounds inducing non-apoptotic cell death for anticancer drug resistance [0.03%]
天然化合物诱导非凋亡细胞死亡以克服抗癌药物抗性的最新进展
Jia-Wen Chen,Sibao Chen,Guo-Qing Chen
Jia-Wen Chen
The induction of cell death is recognized as a potent strategy for cancer treatment. Apoptosis is an extensively studied form of cell death, and multiple anticancer drugs exert their therapeutic effects by inducing it. Nonetheless, apoptosi...
Mechanisms of tyrosine kinase inhibitor resistance in renal cell carcinoma [0.03%]
肾细胞癌中酪氨酸激酶抑制剂耐药的机制
Patrick L Sweeney,Yash Suri,Arnab Basu et al.
Patrick L Sweeney et al.
Renal cell carcinoma (RCC), the most prevalent type of kidney cancer, is a significant cause of cancer morbidity and mortality worldwide. Antiangiogenic tyrosine kinase inhibitors (TKIs), in combination with immune checkpoint inhibitors (IC...
Establishment of head and neck squamous cell carcinoma mouse models for cetuximab resistance and sensitivity [0.03%]
用于建立头颈部鳞状细胞癌小鼠模型的cetuximab耐药性和敏感性研究
Hannah Zaryouh,Ines De Pauw,Hasan Baysal et al.
Hannah Zaryouh et al.
Aim: Acquired resistance to the targeted agent cetuximab poses a significant challenge in finding effective anti-cancer treatments for head and neck squamous cell carcinoma (HNSCC). To accurately study novel combination treatments, suitable...
The clinical challenges of homologous recombination proficiency in ovarian cancer: from intrinsic resistance to new treatment opportunities [0.03%]
同源重组修复在卵巢癌中的临床挑战：从固有耐药到新的治疗机会
Teresa Zielli,Intidhar Labidi-Galy,Maria Del Grande et al.
Teresa Zielli et al.
Ovarian cancer is the most lethal gynecologic cancer. Optimal cytoreductive surgery followed by platinum-based chemotherapy with or without bevacizumab is the conventional therapeutic strategy. Since 2016, the pharmacological treatment of e...